• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CG Oncology, Inc. - Common stock (NQ:CGON)

    74.29 -4.72 (-5.97%)
    Streaming Delayed Price Updated: 3:41 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 312,865
    Open 78.15
    Bid (Size) 74.24 (100)
    Ask (Size) 74.38 (200)
    Prev. Close 79.01
    Today's Range 73.93 - 78.16
    52wk Range 26.04 - 80.97
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup ↗
    Via Chartmill
    News headline image
    CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire

    Performance

    YTD
    +77.8%
    +77.8%
    1 Month
    +2.3%
    +2.3%
    3 Month
    +22.3%
    +22.3%
    6 Month
    +32.4%
    +32.4%
    1 Year
    +180.6%
    +180.6%

    More News

    Read More
    News headline image
    CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead ↗
    Via MarketBeat
    Topics Initial Public Offering
    CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout ↗
    Via Chartmill
    News headline image
    CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push ↗
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    CG Oncology to Present at Upcoming Investor Conferences in June
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears ↗
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings ↗
    Via Benzinga
    News headline image
    CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology to Present at Upcoming Investor Conferences in May
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
    Via The Motley Fool
    News headline image
    This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
    Via MarketMinute
    Topics Earnings Economy
    News headline image
    CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
    Via MarketMinute
    Topics Intellectual Property
    What's going on in today's session ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    News headline image
    CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is CG Oncology, Inc. - Common stock publicly traded?
    Yes, CG Oncology, Inc. - Common stock is publicly traded.
    What exchange does CG Oncology, Inc. - Common stock trade on?
    CG Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for CG Oncology, Inc. - Common stock?
    The ticker symbol for CG Oncology, Inc. - Common stock is CGON on the Nasdaq Stock Market
    What is the current price of CG Oncology, Inc. - Common stock?
    The current price of CG Oncology, Inc. - Common stock is 74.29
    When was CG Oncology, Inc. - Common stock last traded?
    The last trade of CG Oncology, Inc. - Common stock was at 08/28/26 03:41 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.